New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
2018-07-05 · Ionis Pharmaceuticals · original ionis.com ↗
-TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life- -Akcea prepared for launch following approval- CARLSBAD, Calif., and CAMBRIDGE, Mass., July 5, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its affiliate, Akcea Therapeutics (Nasdaq: AKCA), announced today that the final study results from NEURO-TTR, the pivotal study of TEGSEDI™ (inotersen) in patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy, were published in the July 5, 2018 issue of The New England Journal of Medicine in a manuscript titled "Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis."
The release as fetched from its publisher. ionis.com ↗